{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:33:02Z","timestamp":1788870782421,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS075321"],"award-info":[{"award-number":["NS075321"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS41509"],"award-info":[{"award-number":["NS41509"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS058714"],"award-info":[{"award-number":["NS058714"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS48924"],"award-info":[{"award-number":["NS48924"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000448"],"award-info":[{"award-number":["UL1 TR000448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Parkinson Disease Association Advanced Research Center for Parkinson Disease at Washington University in St Louis"},{"DOI":"10.13039\/100008765","name":"Greater St Louis Chapter of the American Parkinson Disease Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008765","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007338","name":"Barnes Jewish Hospital Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007338","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Elliot Stein Family Fund"},{"name":"Parkinson Disease Research Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","neurobiologyofaging.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.neurobiolaging.2014.07.043","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T11:58:58Z","timestamp":1407153538000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Correlation between decreased CSF \u03b1-synuclein and A\u03b21\u201342 in Parkinson disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Chandana","family":"Buddhala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Perlmutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Kotzbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib2","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.neurobiolaging.2010.12.001","article-title":"CSF alpha-synuclein does not differentiate between parkinsonian disorders","volume":"33","author":"Aerts","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp.2009.199950","article-title":"CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study","volume":"81","author":"Alves","year":"2010","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neulet.2012.08.069","article-title":"Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging","volume":"528","author":"Argyriou","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00702-013-1084-z","article-title":"A\u00a0quantitative study of \u03b1-synuclein pathology in fifteen cases of dementia associated with Parkinson disease","volume":"121","author":"Armstrong","year":"2014","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib6","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","article-title":"Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects","volume":"287","author":"Borghi","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.0b013e3181c7da8e","article-title":"In\u00a0vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia","volume":"74","author":"Burack","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archneur.1988.00520250037015","article-title":"Reliability of the Washington University clinical dementia rating","volume":"45","author":"Burke","year":"1988","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.0b013e31829e6f94","article-title":"Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases","volume":"81","author":"Campbell","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib12","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease","volume":"24","author":"Compta","year":"2009","journal-title":"Mov. Disord."},{"issue":"Pt 5","key":"10.1016\/j.neurobiolaging.2014.07.043_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib17","series-title":"Delis Kaplan Executive Function System","author":"Delis","year":"2001"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib18","series-title":"California Verbal Learning Test\u2014II","author":"Delis","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","article-title":"Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography","volume":"79","author":"Edison","year":"2008","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in\u00a0vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/mds.23393","article-title":"Amyloid imaging of Lewy body-associated disorders","volume":"25","author":"Foster","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","article-title":"Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies","volume":"45","author":"Foulds","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.25048","article-title":"Brain amyloid and cognition in Lewy body diseases","volume":"27","author":"Gomperts","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/archneurol.2011.845","article-title":"Exercise engagement as a moderator of\u00a0the\u00a0effects of APOE genotype on amyloid deposition","volume":"69","author":"Head","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/mds.20216","article-title":"Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom","volume":"19","author":"Hobson","year":"2004","journal-title":"Mov. Disord."},{"issue":"Pt 3","key":"10.1016\/j.neurobiolaging.2014.07.043_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOL.0b013e32833af368","article-title":"Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases","volume":"21","author":"Huang","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib34","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","article-title":"Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease","volume":"54","author":"Hurtig","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/13854049608406689","article-title":"Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO","volume":"10","author":"Ivnik","year":"1996","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib36","first-page":"1277","article-title":"Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, p-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib37","series-title":"Boston Naming Test","author":"Kaplan","year":"2001"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JAD-130458","article-title":"Alpha-synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment","volume":"36","author":"Korff","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","article-title":"Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients","volume":"115","author":"Lashley","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib44","series-title":"Neuropsychological Assessment","author":"Lezak","year":"1995"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib45","series-title":"A\u00a0Compendium of Tests and Assessment Techniques","author":"Lezak","year":"2004"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2008.12.008","article-title":"Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics","volume":"34","author":"Maetzler","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroimage.2007.09.072","article-title":"[11C]PIB binding in Parkinson's disease dementia","volume":"39","author":"Maetzler","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib48","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1073\/pnas.211412398","article-title":"Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease","volume":"98","author":"Masliah","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib49","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib50","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/bmm.10.90","article-title":"Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies","volume":"4","author":"Mollenhauer","year":"2010","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.neurobiolaging.2014.07.043_bib54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S1041610297004870","article-title":"Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type","volume":"9","author":"Morris","year":"1997","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib55","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.274.14.9843","article-title":"Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation","volume":"274","author":"Narhi","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00005072-199911000-00004","article-title":"Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease","volume":"58","author":"Newell","year":"1999","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib57","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1074\/mcp.M700158-MCP200","article-title":"Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer","volume":"6","author":"Pan","year":"2007","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease","volume":"7","author":"Park","year":"2011","journal-title":"J.\u00a0Clin. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib59","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid Tau\/alpha-synuclein ratio in Parkinson's disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","article-title":"Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease","volume":"29","author":"Parnetti","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","article-title":"Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease","volume":"6","author":"Parnetti","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib62","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.neurobiolaging.2004.10.006","article-title":"Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases","volume":"26","author":"Pletnikova","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib63","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib64","first-page":"255","article-title":"Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)","volume":"255","author":"Riedel","year":"2008","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib65","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib66","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid {beta}\u00a01-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.10.004","article-title":"Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels","author":"Slaets","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib68","first-page":"213","article-title":"Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease","volume":"26","author":"Tateno","year":"2012","journal-title":"Alzheimer Dis."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib69","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib70","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/mds.25495","article-title":"Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease","volume":"28","author":"van Dijk","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib72","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib73","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated alpha-synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib74","series-title":"Wechsler Adult Intelligence Scale III","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib75","series-title":"Wechsler Memory Scale III","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib76","series-title":"Woodcock-Johnson Tests of Achievement","author":"Woodcock","year":"2001"},{"key":"10.1016\/j.neurobiolaging.2014.07.043_bib77","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1309\/W01Y0B808EMEH12L","article-title":"CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases","volume":"129","author":"Zhang","year":"2008","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458014005120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458014005120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:46:30Z","timestamp":1589240790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458014005120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0197458014005120"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.07.043","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between decreased CSF \u03b1-synuclein and A\u03b21\u201342 in Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.07.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}